Protocol Ledger

NCT03785964 · Phase III · COMPLETED

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Interventional Phase III clinical trial protocol NCT03785964 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-17 Enrollment: 142 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03785964
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)142 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03785964
Protocol FieldVerified Registry Value
NCT IdentifierNCT03785964
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment142 participants (ACTUAL)
Registered Start Date2019-04-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI